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Abstract Everyday, there are several millions of people that
are increasingly unable to combat their frustrating and even
fatal romance with getting high and/or experiencing Bnormal^
feelings of well-being. In the USA, the FDA has approved
pharmaceuticals for drug and alcohol abuse: tobacco and nic-
otine replacement therapy. The National Institute on Drug
Abuse (NIDA) and the National Institute on Alcohol Abuse
and Alcoholism (NIAAA) remarkably continue to provide an
increasing understanding of the intricate functions of brain
reward circuitry through sophisticated neuroimaging and mo-
lecular genetic applied technology. Similar work is intensely
investigated on a worldwide basis with enhanced clarity and
increased interaction between not only individual scientists
but across many disciplines. However, while it is universally
agreed that dopamine is a major neurotransmitter in terms of
reward dependence, there remains controversy regarding how
to modulate its role clinically to treat and prevent relapse for
both substance and non-substance-related addictive behav-
iors. While the existing FDA-approved medications promote
blocking dopamine, we argue that a more prudent paradigm
shift should be biphasic—short-term blockade and long-term
upregulation, enhancing functional connectivity of brain re-
ward circuits.
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Mille viae ducunt homines per saecula Romam (A thousand
roads lead men forever to Rome) in Liber Parabolarum, 591
(1175), by Alain de Lille.
Scientific explorations from around the globe agree that
substance and non-substance-seeking behaviors are consid-
ered an endemic societal problem affecting multimillions.
Certainly, we have come a long way since Bill Wilson and
Dr. Bob Smith began their crusade in 1933 embracing the
BCambridge^ theories and doctrines, resulting in the most
powerful anti-alcohol/drug program and fellowship in the
world—Alcoholics/Narcotic Anonymous. Many years after
Jelnick’s famous article in 1956 providing the medical profes-
sion with the Bconcept of alcoholism as a disease,^ the
American Society of Addiction Medicine (ASAM) espoused
a new definition of addiction indicating that BAddiction is a
primary, chronic disease involving brain reward, motivation,
memory and related circuitry^; it can lead to relapse, progres-
sive development, and the potential for fatality if not treated.
While pathological use of alcohol and, more recently, psycho-
active substances has been accepted as an addictive disease,
developing brain science has set the stage for inclusion of the
process addictions, including food, sex, shopping, and gam-
bling problems, in a broader definition of addiction as set forth
by the American Society of Addiction Medicine in 2011 [1].
To carry out this review, we searched a number of impor-
tant databases including the following: filtered resources—
Cochrane Systematic Reviews, DARE, PubMed Central
Clinical Queries, National Guideline Clearinghouse; unfil-
tered resources—PsychINFO, ACP PIER, PsychSage,
PubMed/MEDLINE. The major search terms included the
following: dopamine agonist therapy for addiction, dopamine
agonist therapy for reward dependence, dopamine antagonis-
tic therapy for addiction, dopamine antagonistic therapy for
reward dependence. Our results produced the following: do-
pamine agonistic therapy for addiction—Cochrane
Systematic Reviews 0, DARE 0, PubMed Central Clinical
Queries 9, National Guideline Clearinghouse 0, PsychINFO
0, ACP PIER 83, PsychSage 15, PubMed/MEDLINE 501;
dopamine agonist for addiction—Cochrane Systematic
Reviews 3, DARE 3, PubMed Central Clinical Queries 10,
National Guideline Clearinghouse 0, ACP PIER 0, PsychSage
15, PubMed/MEDLINE 13; dopamine agonistic therapy for
reward dependence—Cochrane Systematic Reviews 0,
DARE 0, PubMed Central Clinical Queries 1, National
Guideline Clearinghouse 0, PsychINFO 0, ACP PIER 0,
PsychSage 0, PubMed/MEDLINE 62; dopamine agonist for
reward dependence—Cochrane Systematic Reviews 0,
DARE 0, PubMed Central Clinical Queries 337, National
Guideline Clearinghouse 0, PsychINFO 1, ACP PIER 0,
PsychSage 0, PubMed/MEDLINE 120 (see Fig. 1); dopamine
antagonistic therapy for addiction—Cochrane Systematic
Reviews 0, DARE 0, PubMed Central Clinical Queries 0,
National Guideline Clearinghouse 0, PsychINFO 0, ACP
PIER 0, PsychSage 0, PubMed/MEDLINE 633. Clearly, we
utilized a combination of PubMed Central Clinical Queries
and PubMed/MEDLINE for our reliable review search as well
as author searches based on personal knowledge of the field.
According to Belcher et al., drug addiction is characterized
by a compulsive drive to take drugs despite serious negative
consequences and is a disorder that involves complex interac-
tions between genetic and environmental variables [3]. For ex-
ample, undoubtedly, heroin addiction is a complex phenomenon
of the brain involving both affective and cognitive processes [4].
It has been found that in heroin-dependent individuals, there is
increasedwhitematter intensity in the frontal area and decreased
gray matter density in the bilateral prefrontal cortices and in the
temporal regions compared to healthy subjects [5]. It was also
found that there is a high accuracy in the activation pattern
differences between heroin-dependent subjects and healthy
individuals during resting-state brain activities. These differ-
ences of activation patterns included orbitofrontal cortex
(OFC), hippocampal/parahippocampal region, amygdala,
caudate, putamen, as well as the insula and thalamus [6].
Moreover, similar effects were found for alcohol as well.
Specifically, Luhar et al. [7] compared non-smoking non-alco-
holics—alcoholics who smoke had volumetric abnormalities in
pre- and paracentral frontal cortical areas and rostral middle
frontal white matter, parahippocampal and temporal pole re-
gions, the amygdala, the pallidum, the ventral diencephalic re-
gion, and the lateral ventricle. The comorbid group performed
worse than non-smoking non-alcoholics on tests of executive
functioning and on visually based memory tests. Similar find-
ings have been observed with chronic cocaine [8], food abuse
[9], and other addictive behaviors [10].
Importantly, Volkow et al. [11] proposed a map consisting of
four circuits involved in drug abuse and possibly reward behav-
iors (i.e., addiction): (1) reward, located in the nucleus accum-
bens (NAc) and ventral pallidum; (2) motivation/drive, located in
the OFC and subcallosal cortex; (3) memory and learning, locat-
ed in the amygdala and hippocampus; and (4) control, located in
the prefrontal cortex and anterior cingulate gyrus (ACC).
Our current knowledge indicates that whereas aberrant
craving behavior resides in the caudate-accumbens brain re-
gion, loss of control and thus relapse occur in the cingulated
gyrus [12]. Moreover, Thanos et al. [13] as well as Rothman
et al. [14] independently suggested that dopamine agonist
therapy by either increasing D2R availability or enhanced
dopamine release could be a useful therapeutic adjunct for
the treatment of cocaine, alcohol, heroin addictions, as well
as for obesity, attention deficit disorder, and depression or
reward deficiency syndrome (RDS) behaviors [15].
We hypothesized that the putative natural anti-craving/anti-
relapse compound KB220Z™ as reviewed by Chen et al. [16]
may activate dopaminergic pathways. This complex is a
neuroadaptagen comprising amino acid neurotransmitter pre-
cursors and enkephalinase-catecholamine-methyl-transferase
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(COMT)-MAO-inhibition therapy called neuroadaptagen
amino acid therapy (NAAT). A number of KB220 variants,
developed in the late 1980s, have been the subject of approx-
imately 27 clinical trials (see review [17]).
Ongoing research on KB220Z™ repeatedly confirms the
numerous clinical effects that ultimately result in significant
benefits for victims having genetic antecedents for all addic-
tive, compulsive, and impulsive behaviors [18]. In earlier re-
search in the USA using qEGG in protracted abstinence in
psychostimulant-dependent subjects, this compound showed
an increase in both alpha and low beta bands in the OFC and
cingulated gyrus, overcoming qEEG abnormalities [19] also
seen with alcoholics and heroin addicts [20].
We are cognizant that risk for relapse has now been linked
to hypodopaminergic genetics. Dani et al. [21] suggested that
withdrawal from nicotine induces a hypodopaminergic state,
but there is a relative increase in the sensitivity to phasic do-
pamine release that is caused by nicotine. Therefore, acute
nicotine reexposure causes a phasic dopamine (DA) response
that more potently reinforces relapse to smoking during the
withdrawal period. The supersensitivity to DA in terms of
relapse has been the subject of a number of articles, whereas
our laboratory suggested that relapse to psychoactive drugs is
due to a process called deprivation-amplification relapse ther-
apy (DART) [22]. We proposed that low D2 receptor density
and polymorphisms of the D2 gene are associated with risk for
relapse of substance abuse, including alcohol dependence,
heroin craving, cocaine dependence, methamphetamine
abuse, nicotine sensitization, and glucose craving. We further
proposed that a putative physiological mechanism that may
help to explain the enhanced sensitivity following intense
acute dopaminergic D2 receptor activation is denervation
supersensitivity. This concept is in agreement with the work
of Dahlgren et al. [23] who reported that alcoholic carriers of
the Taq A1 allele of the dopamine D2 receptor gene compared
to Taq A2 allele carriers significantly relapse at a higher rate,
suggesting a hypodopaminergic trait. Unfortunately, Taq A1
allele alcoholics have a significant enhanced mortality rate
[24] as well as cocaine addicts [25]. Historically, the notion
that low dopaminergic function is linked to substance and
non-substance-seeking behavior is well known, and this con-
cept dates back to the dopamine depletion hypothesis es-
poused by Dackis and Gold [26] to explain cocaine relapse.
More recently, others have indicated that carriers of the dopa-
mine D2 receptor Taq A2 allele have a reduced risk for all
RDS behaviors including glucose craving and as such is pro-
tective [27, 28].
Over the last decade, a number of scientists pioneered the
controversial concept that food addiction and drug addiction
constitute common neurobiological mechanisms [29, 30].
Avena [31] reported on similar neurochemical changes during
withdrawal from both heroin and sugar binging. The role of
dopamine release and sugar binging seems interconnected as
evidenced by the attenuation of palatable food seeking by an
inhibitor of aldehyde dehydrogenase inhibitor-2 which also
blocks DA release at the NAc [32]. While this may have some
clinical relevance in the short term (i.e., reducing sugar bing-
ing), we caution long-term benefits because of anti-reward/
dark side of addiction/deficiency of dopaminergic function
[33, 34] and potential mood changes including suicide idea-
tion [35]. Alternatively, we propose herein that dopamine ag-
onistic, not antagonistic, therapy in the long term will be more
prudent. We must ask the following question: Are we serving
enough Bdopamine for dinner^?
In earlier days, it was true that all roads did lead to Rome.
This simple truth is not too dissimilar when we consider the
Homo sapiens reward circuitry of the brain. Based on numer-
ous experiments in the scientific literature, well over 20,000
entries, the major reward neurotransmitter pathway (road) in-
deed is DA [36].
The role of dopamine and mind function has been fraught
with controversy but arguably very interesting and mind
Fig. 1 Schematic of the brain reward cascade: normal and abnormal
representation. a The normal physiologic state of the neurotransmitter
interaction at the mesolimbic region of the brain. Briefly, serotonin in
the hypothalamus stimulates neuronal projections of methionine
enkephalin in the hypothalamus that, in turn, inhibits the release of
GABA in the substantia nigra, thereby allowing for the normal amount
of dopamine to be released at the nucleus accumbens (NAc) reward site of
the brain. b Hypodopaminergic function of the mesolimbic region of the
brain. The hypodopaminergic state is due to gene polymorphisms as well
as environmental elements (epigenetics), including both stress and
neurotoxicity from aberrant abuse of psychoactive drugs (i.e., alcohol,
heroin, cocaine, etc.) and genetic variables [2]
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expanding. There are many unanswered questions related to
what makes us human and what drives our unique behaviors.
While many brain theories have focused on the role of brain
size and genetic adaptations, Fred Previc, a scientist living in
San Antonio, TX, explored the provocative and very specula-
tive concept of a Bdopaminergic society^ [37].
According to Previc, the dopaminergic mind hypothesis
seeks to explain the differences between modern humans and
their hominid relatives by focusing on changes in dopamine. It
theorizes that increased levels of dopamine were part of a gen-
eral physiological adaptation due to an increased consumption
of meat around two million years ago inHomo habilis and later
enhanced by changes in diet and other environmental and social
factors beginning approximately 80,000 years ago. Under this
theory, the Bhigh-dopamine^ personality is characterized by
high intelligence, a sense of personal destiny, a religious/
cosmic preoccupation, an obsession with achieving goals and
conquests, an emotional detachment that in many cases leads to
ruthlessness, and a risk-taking mentality. High levels of dopa-
mine are proposed to underlie increased psychological disor-
ders in industrialized societies. According to this hypothesis, a
dopaminergic society is an extremely goal-oriented, fast-paced,
and even manic society, Bgiven that dopamine is known to
increase activity levels, speed up our internal clocks, and create
a preference for novel over unchanging environments.^ In the
same way that high-dopamine individuals lack empathy and
exhibit a more masculine behavioral style, dopaminergic soci-
eties are Btypified by more conquest, competition, and aggres-
sion than nurturance and communality.^
In our view, the lack of brain dopamine function (dopamine
deficiency) either due to genetics and/or environmental ele-
ments (epigenetics) could lead to a Bhypodopaminergic
society^ whereby the individual may have a reduced cogni-
tion and memory, poor executive function, lack of motivation
or achieving goals, low spirituality, liberal non-partisan views,
selfishness, high novelty seeking, substance and behavioral
reward seeking, lack of attention span, violent behavior, com-
promised well-being and blunted ability to achieve pleasure
states, erotic love styles (less romantic in nature), enhanced
immature defense style (lying), lowered pain tolerance, higher
percent body fat, less energy, and basically unhappy (see brain
reward cascade schematic Fig. 1).
Although behavioral evidence and some indirect ana-
tomical evidence revealed by the work of SI Rapoport from
the Laboratory of Neurosciences, National Institute on
Aging, National Institutes of Health, Bethesda, MD (e.g.,
enlargement of the dopamine-rich striatum in humans),
support a dopaminergic expansion in humans [38], accord-
ing to MA Raghanti and associates from the Department of
Anthropology at Kent State in Ohio, there is still no direct
evidence that dopamine levels are markedly higher in
humans relative to other apes [39]. However, recent discov-
eries about the seaside settlements of early man may
provide evidence of dietary changes consistent with this
hypothesis [40].
The possibility does exist that prehistoric ancestral species
over two million years ago carried the low dopamine brain
function due to low dopamine receptors. It should be noted
that dopamine functions as a neurotransmitter activating the
five known types of dopamine receptors—D1–D5—and their
variants. Dopamine from L-tyrosine found in meat is produced
in several areas of the brain, including the Bbrain reward^
(nucleus accumbens) site located in the reptilian old brain
region called the mesolimbic system. Scientists now know
that there are two major variant forms of the human gene,
for example, the dopamine D2 receptor gene (DRD2) that
regulates the synthesis of D2 receptors and the most widely
studied gene that accounts for major aspects of modern human
behavior [41]. Specifically, there is DRD2 A2 form which in
today’s world is considered the Bnormal^ variation carried by
two thirds of the US population, whereas the DRD2 A1 form
carried by one third of today’s US population results in 30–
40 % lowered D2 receptors and as such leads to a subset of
approximately 100 million people that constitute the Blow-
dopamine society^ [42]. It is parsimonious to consider that
the older gene form (DRD2 A1) leading to low dopamine
function may have afforded certain survival benefits, but as
H. habilis increased their meat consumption, feeding the brain
with the needed L-tyrosine to synthesize more dopamine re-
quired to overcome the D2 receptor deficit, a new society was
born—the Bhigh-dopamine society^ carrying the DRD2 A2
form of this gene. The differences between carriers of the low-
dopamine-expressing gene form A1 compared to the normal
or higher expression of the dopamine D2 receptor gene A2
have been shown to be protective against ADHD, a subtype of
RDS behavior [28].
Understanding that low dopamine function leads to impul-
sive, compulsive, and addictive behaviors paves the way to
defining addiction as a brain disorder involving impairments
in the so-called reward circuitry. This new definition of addic-
tion has been now adopted by the American Society of
Addiction Medicine (ASAM) founded by the San
Franciscan visionary David E. Smith [1]. This new definition
is based in part on the initial conceptualization of one of us
(KB), who in 1995 coined Breward deficiency syndrome^
(RDS) [43], a term to define common genetic antecedents
for a predisposition for aberrant substance and behavioral
seeking. This list is remarkable, and it may lead to alco-
holism, opiate dependence, psychostimulant abuse (e.g.,
cocaine), nicotine dependence, glucose binging and over-
eating, inability to focus (ADHD and other spectrum dis-
orders), pathological gambling, excessive Internet gaming,
sex addiction, and obsessive-compulsive disorder, among
other repetitive known behaviors.
While having any brain genetic deficit in the reward site
may predispose an individual to a higher risk for RDS, it
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is always the combination of our genes and the interaction with
environmental elements that predict not only addictive behav-
iors in general but specificity of the type of drug or behavior of
choice. Using a special mathematical formulation (Bayesian—
developed by a sixteenth-century monk) to predict the value of
carrying for example the DRD2 A1 (low D2 receptors) at birth
and subsequent lifetime, the risk of any RDS behavior has been
determined to be as high as 74 % [44].
Thus, our provocative hypodopaminergic RDS theory is
highly impacted by what scientists like Steve Sussman of
Southern California University call epigenetic factors
(environmental) rather than just genetic factors and translation
to preventive strategies [45] for school children and others
[46] involved in epigenetics from a cellular exploration. So,
the take-home message is that while one is not doomed be-
cause of their genes to become an addict, they are definitely at
high risk and as such may require this genetic knowledge
earlier than later in life.
The FDA-approvedmedications for alcohol, drugs, and food
are at best only moderately effective and in some cases counter
to promoting Bdopamine homeostasis^ including narcotic an-
tagonists and acamprosate, a NMDA antagonist, for example,
utilized to reduce drug-induced euphoria via attenuated neuro-
nal dopamine release at the NAc [47, 48].We argue the work of
Shelton et al. [49] who suggested that the known anxiolytic
buspirone may reduce the likelihood of relapse to cocaine and
methamphetamine use under some conditions, especially for
adolescents. Our concern with this concept is that understand-
ing the pharmacological complexity of this substance involving
serotonin 5-HT1A receptor partial agonist activity and dopa-
mine D2, D3, and D4 receptor antagonist effects thereby reduc-
ing availability of dopamine seems counterintuitive.
Our laboratory extensively published on the concept of
dopamine agonist therapy to treat iatrogenic opioids and even
prevent RDS behaviors [50]. A major challenge in effectively
utilizing chronic dopamine agonist therapy is the manner in
which powerful D2 agonists like bromocriptine work to ulti-
mately reduce D2 receptor density [51]. In agreement with
dopamine agonist therapy is the recent work of Maguire
et al. [52] showing the interactive role of D1 and D2 receptor
activation in affecting synaptic GABAA receptors within the
NAc altering GABA’s inhibition of medium spiny neurons
subsequently influencing behavioral responses to cocaine.
While utilization of dopamine agonists may be complicated,
it is of interest that Czoty and Nader [53] clearly showed the
differences between a low-dopamine agonist compared to a
high-dopamine agonist in terms of blocking food-cocaine
choice in socially housed male cynomolgus monkeys primar-
ily favoring the low agonist compared to the high agonist.
Moreover, Radke and Gewirtz [54] showed that increasing
dopamine receptor activity in the NAc shell utilizing known
dopamine D2 agonists significantly ameliorates anxiety dur-
ing withdrawal from morphine and nicotine. This work is
underscored by an earlier work from Thanos et al. [55–57]
showing attenuation of alcohol and cocaine intake by gene
therapy. Along similar lines, Crunelle et al. [58] showed that
varenicline (a partial agonist at α4β2 nicotinic acetylcholine
receptors) significantly increases the availability of D2/D3
receptors and concomitantly reduces nicotine-seeking behav-
ior. Interestingly, van Rijn et al. [59] found that the delta opi-
oid receptor agonist (selective DOR agonists) can decrease
anxiety-like behavior and reduce ethanol consumption. This
is important when you factor in the interaction of opioid re-
ceptor activity and inhibition of GABA transmission at the
substantia nigra [60]. In further support of our hypothesis,
Carvalho et al. [61] observed that long-term haloperidol ad-
ministration to mice resulted in enhanced addiction-related
behaviors due to a suspected supersensitivity induced by
prolonged D2 blockade favoring our DART concept [22].
It is also known that cocaine reinstatement occurs only with
D1 receptor agonists, not D2 receptor agonists, and as such
Graham et al. [62] provide clear evidence for this differential
effect which is underscored by others [63]. This work is
highlighted by Caine et al. [64] who reported that in wild-
type mice, pretreatment with the D2-like antagonist eticlopride
increased rates of self-administration of high doses of cocaine,
and the D2-like agonist quinelorane served as a positive rein-
forcer when substituted for cocaine, supporting dopamine D2
agonist therapy.
In humans, Schmidt et al. [65] reported that the dopamine
D2 agonist lisuride prolonged the latency of relapse, whereby
the authors suggested that alcoholics may relapse due to de-
creased dopamine function. In addition, Koob’s group [66]
showed that pretreatment with the dopamine D2 receptor ag-
onist bromocriptine attenuated the cocaine-induced increase
in responding for the cocaine-associated cue. In contrast, pre-
treatment with low doses of SDZ 208-911, a dopamine D2
partial agonist reducing D2 receptor availability, further po-
tentiated the cocaine-induced response. Further work in
humans by Lawford et al. [67] showed that D2 agonist therapy
with bromocriptine prevented relapse in alcoholics especially
those that carry the DRD2 A1 allele, indicating that low do-
pamine function responds best compared to normal D2 recep-
tor density in A2 carriers.
The work of Ng and George [68] firmly supports a dopa-
mine hypothesis for ethanol abuse in the genetically ethanol-
preferring C57 mouse as argued by Blum et al. in earlier
experiments [69]. While there is still controversy concerning
how best to treat RDS as it relates to drug seeking and relapse
especially in terms of dopaminergic function [70], based on
our experience involving a natural putative dopamine agonis-
tic pharmacological profile [17] and human neuroimaging
studies (qEEG and fMRI) [17, 19, 20], we are hereby propos-
ing that following required research, short-term blockade of
D2 receptors is prudent but long-term treatment should acti-
vate, not block, D2 receptors.
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Understanding the true role of dopamine in escalating, for
example, cocaine has been the recent subject of investigation
by a number of investigators. Weiss’s group provided strong
evidence that attenuated dopamine actions in the core (but not
the shell) of accumbens result in greater cocaine intake—
shorter interresponse times—during periods of self-
administration [71]. Conversely, they find that enhanced do-
pamine actions in the core (but not the shell) result in de-
creased intake—longer interresponse times [72]. In agreement
with these findings, Willuhn et al. [73] surprisingly found that
phasic dopamine decreased in the ventromedial striatum
(VMS) as the rate of cocaine intake increased, with the decre-
ment in dopamine in the VMS significantly correlatedwith the
rate of escalation. Moreover, the administration of the dopa-
mine precursor L-DOPA at a dose that replenished dopamine
signaling in the VMS reversed escalation, thereby demonstrat-
ing a causal relationship between diminished dopamine trans-
mission and excessive drug use. While this work is intriguing,
it may not morph other theories such as the surfeit rather than
deficit dopamine function; however, it does seem to support
dopamine-based agonistic modalities as suggested byWilluhn
et al. [73]. Along these lines, Caprioli et al. [74] correctly
conclude that, at present, there are no FDA-approved medica-
tions for cocaine addiction. However, several clinical studies
have suggested that agonist-based substitution treatment (for
example, prescription oral amphetamine) decreases illegal co-
caine use [75]. While we do not clinically agree with the
amphetamine approach (chronically leading to downregula-
tion of D2 receptors as seen with other D2 agonists [76]), it
does point out the importance of dopamine agonist therapy
compared to current theories utilizing dopamine antagonistic
therapy to treat cocaine escalation during protracted
abstinence.
Epigenetics, an emerging area in the neuroscience field, has
provided important clues about how drugs of abuse including
alcohol interact with epigenome and modulate the genetic
functions and regulate addictive endophenotypes [77, 78].
Epigenetic modifications, such as histone and DNA chemical
modifications, also play an important role in neurodevelopment
[79, 80]. Epigenetics explains how environmental and psycho-
logical factors regulate the activity of our genome without in-
ducing changes in the DNA sequence. It has been suggested
that epigenetics mediates our behavior, in part, and has long-
term effects on the regulation of the genome function. In fact,
González-Pardo and Pérez Álvarez [81, 82] indicate that epi-
genetics impacts nature-nurture, genotype-phenotype, or path-
ogenesis-pathoplasty.
One important outcome of this concept has been adopted
by a new cook book entitled Dopamine for Dinner [76]
responding to the question: Are we serving enough dopamine
for dinner? As scientists interested in our most troublesome
issues in psychiatry, reward deficiency, and sports medicine,
we encourage others to have an open mind and continue to
research this worthy area of investigation that will potentially
Bredeem joy^ to RDS victims all over the world.
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